Xenetic Biosciences, Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended June 30, 2015. Xenetic is a clinical-stage biopharmaceutical company developing drug-delivery platforms and drug candidates, including PolyXen, OncoHist and ImuXen. No candidate had received marketing approval, and the company reported no revenue in either the quarter or first half of 2015.
Financial results and position
| Metric | Q2 2015 | Q2 2014 | Six months 2015 | Six months 2014 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development | $0.56 million | $1.03 million | $1.59 million | $1.60 million |
| General and administrative | $0.80 million | $1.61 million | $1.74 million | $4.00 million |
| Operating loss | $1.36 million | $2.64 million | $3.33 million | $5.60 million |
| Net loss | $1.13 million | $2.76 million | $3.56 million | $6.82 million |
| Basic and diluted loss per share | $0.01 | $0.02 | $0.03 | $0.05 |
Margins: Revenue was zero, so revenue margins are not meaningful. The company remains pre-commercial and loss-making.
At June 30, 2015, cash was $301,480 (versus $2.51 million at December 31, 2014); restricted cash was $66,000. Current assets were $498,343 and current liabilities were $3.47 million, producing a reported working-capital deficit of approximately $3.0 million. Total assets were $13.27 million, total liabilities $6.44 million, and stockholders’ equity $6.83 million.
For the six months, operating cash outflow was $2.23 million, investing activities provided $4,583, financing activities provided $100,000, and cash declined by $2.21 million. No meaningful revenue or product gross margin was reported. The filing does not provide a clear standalone debt total; current liabilities included a $395,000 related-party loan, and the company also had a $100,000 short-term note issued in June and repaid in July.
Changes versus comparable periods
- Q2 net loss narrowed by 59% year over year; first-half net loss narrowed by 48%. The first-half comparison benefited in part from the absence of the $1.07 million loss on disposal of subsidiaries recorded in 2014.
- Q2 R&D spending fell 46%, primarily because OncoHist IND-enabling work was deferred amid working-capital constraints. First-half R&D was nearly unchanged year over year.
- G&A fell 50% in Q2 and 56% in the first half, reflecting lower legal, professional, accounting, regulatory and transition costs as the company’s move from the U.K. to the U.S. was substantially completed in 2014.
- Cash fell substantially from year-end, and the company moved from $78,000 of working capital at December 31, 2014 to a $3.0 million deficit at June 30, 2015.
Outlook, risks and unusual items
- Going concern and financing: Management said additional working capital was required to meet obligations for the next 12 months and disclosed substantial doubt about the company’s ability to continue as a going concern without further financing. It was negotiating additional bridge financing; success and terms were uncertain.
- Subsequent financing: In July 2015, Xenetic issued Pharmsynthez a $3 million, 10% senior secured collateralized convertible note, due in one year and convertible at the holder’s option at $0.15 per share. The financing included a five-year warrant for 10 million shares, exercisable beginning January 1, 2016. If the note is not repaid or converted within six months, an additional warrant for 10 million shares may be issued.
- Related-party obligations: SynBio agreed after quarter-end to defer collection efforts on its $395,000 loan until the earlier of January 31, 2016 or completion of a $7 million financing. A $485,000 trade payable was disputed by the company.
- Commercial and clinical prospects: Management did not expect significant collaboration receipts before 2016; possible Baxalta payments depend on clinical-development milestones. It did not expect new ErepoXen out-licensing income before Q1 2016 at the earliest. Both timing and receipt of these amounts were uncertain.
- Development plans: Xenetic planned to pursue an OncoHist AML IND filing in the first half of 2016, subject to financing and completion of preclinical work. The company reported that the Russian AML trial had stopped after a change in standard of care; the study report was in progress. ErepoXen clinical trials in Australia and a MyeloXen trial in Russia were ongoing.
- Accounting correction: The company identified foreign-currency and pushdown-accounting errors, concluded the revisions were not material to the periods presented, and recognized the cumulative impact in the current period. The correction contributed a $0.24 million net gain in other income for the first half and affected accumulated other comprehensive income.
- Other risks and governance: Clinical, regulatory, financing, competition, intellectual-property and collaboration risks remain significant. The chairman resigned in April 2015, and the position was vacant at filing. Management reported disclosure controls were effective at a reasonable-assurance level and no material change in internal control over financial reporting.
Important facts for investors to verify
- Cash runway, near-term obligations and whether additional financing beyond the July $3 million note was secured on acceptable terms.
- The note’s collateral, conversion and warrant provisions, including potential additional warrant issuance and resulting dilution.
- The status and resolution of the disputed $485,000 payable and the deferred $395,000 SynBio loan.
- Clinical and regulatory milestones for OncoHist, ErepoXen and MyeloXen, and whether collaboration or out-licensing payments become collectible.
- The company’s post-quarter share count and fully diluted capitalization: the filing reports 139,297,282 shares outstanding at June 30 and 150,513,011 as of August 14, 2015.
- The foreign-currency accounting correction and its effects on reported results, accumulated other comprehensive income and comparability.